{
    "patient": {
        "Name": "Mary West",
        "DateOfBirth": "1999-01-23",
        "Sex": "Female",
        "Diagnosis": "Medullary thyroid cancer",
        "BodyPart": "Thyroid",
        "Physician": "Dr. Katie Brown",
        "TreatingInstitution": "Wilson and Sons"
    },
    "specimen": {
        "Tumor specimen": {
            "source": "Thyroid",
            "CollectedDate": "2024-04-18",
            "ReceivedDate": "2024-04-21",
            "TumorPercentage": "6%"
        },
        "Normal specimen": {
            "source": "Blood",
            "CollectedDate": "2024-04-19",
            "ReceivedDate": "2024-04-19"
        }
    },
    "genomic variants": {
        "Somatic - Potentially Actionable": [
            {
                "Gene": "ALDH2",
                "DNA Alteration": "c.1510G>A",
                "GeneMutation": "p.E504K Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "20.85%"
            },
            {
                "Gene": "MYO1G",
                "DNA Alteration": "c.145G>A",
                "GeneMutation": "p.V49M Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "25.75%"
            },
            {
                "Gene": "BRCA1",
                "DNA Alteration": "c.68_69delAG",
                "GeneMutation": "p.E23Vfs*17 Nonsense-GOF",
                "VariantAlleleFraction": "15.62%"
            },
            {
                "Gene": "NT5C2",
                "DNA Alteration": "c.1100G>A",
                "GeneMutation": "p.R367Q Frameshift-GOF",
                "VariantAlleleFraction": "24.27%"
            }
        ],
        "Somatic - Biologically Relevant": [
            {
                "Gene": "BTK",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.C481X Frameshift-GOF",
                "VariantAlleleFraction": "13.58%"
            },
            {
                "Gene": "CHEK2",
                "DNA Alteration": "c.1283C>T",
                "GeneMutation": "p.S428F Nonsense-GOF",
                "VariantAlleleFraction": "5.12%"
            },
            {
                "Gene": "CSF3R",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R367Q Spliceregionvariant-GOF",
                "VariantAlleleFraction": "6.82%"
            }
        ],
        "Germline - Pathogenic": [],
        "Pertinent Negatives": [
            "ARHGAP45",
            "RNF43"
        ]
    },
    "immunotherapy markers": [
        {
            "marker_name": "Tumor Mutational Burden",
            "TmbValue": "41 m/Mb",
            "Tmbpercentile": "61%",
            "Status type": "Microsatellite Instability Status",
            "statusvalue": "Equivocal"
        }
    ],
    "FDA-Approved Therapies": {
        "Current Diagnosis": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ],
        "Other Indications": [
            {
                "Mechanism": "KRAS G12C Inhibitors",
                "Medication": "Sotorasib",
                "Recommendations": [
                    "NCCN, Consensus, Non-Small Cell Lung Cancer",
                    "MSK OncoKB, Level 1"
                ],
                "Relevant Mutation": "KRASp.G12C G12C-GOF"
            }
        ]
    },
    "Additional Indicators": [
        {
            "description": "Unfavorable Prognosis",
            "therapy": "NCCN, Consensus, Non-Small Cell Lung Cancer",
            "mutation": "KRASp.G12C Gain-of-function"
        }
    ],
    "Clinical trials": [
        {
            "description": "A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent G12V, Other KRAS and BRAF Non-Small Cell Lung Cancer ",
            "phase": "Phase 2",
            "mutations": [
                "KRAS"
            ]
        },
        {
            "description": "A Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1",
            "phase": "Phase 1/2",
            "mutations": [
                "KRAS",
                "STK11"
            ]
        },
        {
            "description": "First-in-human Study of DRP-104 (Sirpiglenastat) as Single Agent and in Combination With Atezolizumab in Patients With Advanced Solid Tumors. (NCT04471415)",
            "phase": "Phase 1/2",
            "mutations": [
                "NFE2L2",
                "STK11"
            ]
        }
    ],
    "variants of unknown significance": {
        "Somatic": [
            {
                "Gene": "KRAS",
                "DNA Alteration": "c.34_36delinsTGG",
                "GeneMutation": "p.A146T Spliceregionvariant-LOF",
                "VariantAlleleFraction": "6.02%"
            },
            {
                "Gene": "MUTYH",
                "DNA Alteration": "c.1014G>C",
                "GeneMutation": "p.Q338H Missensevariant(exon2)-GOF",
                "VariantAlleleFraction": "3.23%"
            },
            {
                "Gene": "CALR",
                "DNA Alteration": "c.1092_1143del52",
                "GeneMutation": "p.L367fs*46 Nonsense-GOF",
                "VariantAlleleFraction": "10.1%"
            },
            {
                "Gene": "BRAF",
                "DNA Alteration": "c.1799_1800delinsAA",
                "GeneMutation": "p.L597R Nonsense-GOF",
                "VariantAlleleFraction": "6.8%"
            },
            {
                "Gene": "MUTYH",
                "DNA Alteration": "c.1014G>C",
                "GeneMutation": "p.Q338H Frameshift-LOF",
                "VariantAlleleFraction": "4.11%"
            },
            {
                "Gene": "CSF3R",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.G751A Frameshift-LOF",
                "VariantAlleleFraction": "6.45%"
            },
            {
                "Gene": "MPL",
                "DNA Alteration": "c.1544G>T",
                "GeneMutation": "p.W515K Nonsense-LOF",
                "VariantAlleleFraction": "9.55%"
            },
            {
                "Gene": "CALR",
                "DNA Alteration": "c.1092_1143del52",
                "GeneMutation": "p.L367fs*46 Spliceregionvariant-LOF",
                "VariantAlleleFraction": "1.37%"
            },
            {
                "Gene": "SDHD",
                "DNA Alteration": "c.34G>A",
                "GeneMutation": "p.G12S Frameshift-GOF",
                "VariantAlleleFraction": "4.9%"
            },
            {
                "Gene": "TLR8",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.N515H Nonsense-GOF",
                "VariantAlleleFraction": "2.55%"
            }
        ],
        "Germline": []
    },
    "low coverage regions": [
        "CSF1R",
        "DDR2",
        "CD74"
    ],
    "genomic variants details": {
        "Somatic Variant Details - Potentially Actionable": [
            {
                "Gene": "ALDH2",
                "DNA Alteration": "c.1510G>A",
                "GeneMutation": "p.E504K Missensevariant(exon2)-GOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "20.85%"
            },
            {
                "Gene": "MYO1G",
                "DNA Alteration": "c.145G>A",
                "GeneMutation": "p.V49M Missensevariant(exon2)-GOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "25.75%"
            },
            {
                "Gene": "BRCA1",
                "DNA Alteration": "c.68_69delAG",
                "GeneMutation": "p.E23Vfs*17 Nonsense-GOF",
                "description": "ARID2 encodes a protein that is a subunit of the SWI/SNF chromatin remodeling complex SWI/SNF-B or PBAF. This complex functions in ligand-dependent transcriptional activation. Loss of function mutations and copy number loss of ARID2 are associated with cancer progression.",
                "VariantAlleleFraction": "15.62%"
            },
            {
                "Gene": "NT5C2",
                "DNA Alteration": "c.1100G>A",
                "GeneMutation": "p.R367Q Frameshift-GOF",
                "description": "RBM10 encodes a protein that contains a RNA-binding motif and interacts with RNA homopolymers, and is thought to function in regulating alternative splicing. Loss of function mutations and copy number loss of RBM10 are associated with cancer progression.",
                "VariantAlleleFraction": "24.27%"
            }
        ],
        "Somatic Variant Details - Biologically Relevant": [
            {
                "Gene": "BTK",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.C481X Frameshift-GOF",
                "description": "FAT1 encodes a transmembrane protein involved in tumor suppressor signaling. FAT1 protein can regulate transcriptional activity by sequestering beta-catenin, thereby preventing it from entering the nucleus. Loss of function mutations and copy number loss of FAT1 are associated with cancer progression.",
                "VariantAlleleFraction": "13.58%"
            },
            {
                "Gene": "CHEK2",
                "DNA Alteration": "c.1283C>T",
                "GeneMutation": "p.S428F Nonsense-GOF",
                "description": "STK11 (LKB1) encodes an enzyme in the serine/threonine kinase family that is responsible for maintaining energy metabolism and cellular polarization through the activation of AMP-activated protein kinase and other members of the AMPK family. The enzyme also acts as a tumor suppressor by regulating cell growth. Loss of function mutations, copy number loss, epigenetic variation, and underexpression of STK11 are associated with cancer progression.",
                "VariantAlleleFraction": "5.12%"
            },
            {
                "Gene": "CSF3R",
                "DNA Alteration": "c.3113A>G",
                "GeneMutation": "p.R367Q Spliceregionvariant-GOF",
                "description": "KRAS is a GDP/GTP binding protein that acts as an intracellular signal transducer. KRAS is involved in several pathways involved in cellular proliferation and survival, including the PI3K-AKT-mTOR pathway and the Ras-Raf-MEK-ERK pathway. Activating mutations, copy number gains, and overexpression of KRAS are associated with cancer progression.",
                "VariantAlleleFraction": "6.82%"
            }
        ]
    },
    "clinical history": {
        "Date": "2024-04-17"
    },
    "other": {
        "ReportId": "5371",
        "ReportDate": "2024-04-18",
        "SignedBy": "Katie Brown",
        "Supervisor": "Dr. Jamie Wilcox"
    }
}